A5103144297- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Inhalation and Respiratory Drug Delivery
- Hormonal Regulation and Hypertension
- Pharmaceutical studies and practices
- Adrenal and Paraganglionic Tumors
- Cancer Immunotherapy and Biomarkers
- Ocular Surface and Contact Lens
- IL-33, ST2, and ILC Pathways
- Systemic Lupus Erythematosus Research
- Respiratory and Cough-Related Research
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Sinusitis and nasal conditions
- PI3K/AKT/mTOR signaling in cancer
- Cytokine Signaling Pathways and Interactions
- Retinal Diseases and Treatments
- Pharmacological Effects and Toxicity Studies
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Drug-Induced Adverse Reactions
- Lung Cancer Diagnosis and Treatment
- Drug Transport and Resistance Mechanisms
- Renal cell carcinoma treatment
Indiana University Bloomington
2025
Harbin Medical University
2021-2024
First Affiliated Hospital of Harbin Medical University
2021-2024
First Affiliated Hospital of Gannan Medical University
2022-2024
Sichuan University
2024
State Key Laboratory of Oral Diseases
2024
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
2022-2023
Kunming University of Science and Technology
2022-2023
Kunming University
2023
Chongqing University of Technology
2022
Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE hyperproduction and eosinophilic inflammation. The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients CRSwNP comorbid asthma previously.Our aim was to determine omalizumab safety phase 3 trials (POLYP 1 POLYP 2).Adults inadequate response intranasal corticosteroids were randomized (1:1) or placebo mometasone for 24 weeks. Coprimary end points included change from baseline week Nasal Polyp Score (NPS)...
Purpose To the best of our knowledge, this study is first to compare dual inhibition PI3K/mammalian target rapamycin (mTOR) by apitolisib (GDC-0980) against single mTORC1 everolimus in metastatic renal cell carcinoma (mRCC). Patients and Methods with clear-cell mRCC who progressed on or after vascular endothelial growth factor–targeted therapy were randomly assigned 40 mg once per day 10 day. End points included progression-free survival, safety, overall objective response rate. Biomarker...
Background: Quilizumab, a humanized IgG1 monoclonal antibody, targets the M1-prime segment of membraneexpressed IgE, leading to depletion IgE-switched and memory B cells.In patients with mild asthma, quilizumab reduced serum IgE attenuated early late asthmatic reaction following whole lung allergen challenge.This study evaluated efficacy safety in adults allergic inadequately controlled despite high-dose inhaled corticosteroids (ICS) second controller.Methods: Five hundred seventy-eight were...
BACKGROUND The current single‐arm, open‐label trial was designed to evaluate the activity of apitolisib (GDC‐0980), a dual phosphoinositide 3‐kinase/mammalian target rapamycin (PI3K/mTOR) inhibitor, in patients with advanced endometrial cancer (EC). METHODS Patients recurrent or persistent EC who were treated 1 2 prior lines chemotherapy but no PI3K/mTOR inhibitor received oral at dose 40 mg daily during 28‐day cycles until disease progression intolerable toxicity occurred. type I/II...
ABSTRACT The increasing evidences showed that adverse early life events have profound long lasting consequences in adult rats including neural, behavioral, and cognitive effects. Early maternal separation was one of the models stress, but which period acts critically unknown until now. purpose this paper to explore effects different periods, is, postnatal Day 2–9 14–21, on spatial learning memory long‐term potentiation (LTP) hippocampus adolescent rats. Rat pups were assigned three groups:...
BackgroundThe Janus kinase (JAK) pathway mediates the activity of many asthma-relevant cytokines, including IL-4 and IL-13. GDC-0214 is a potent, inhaled, small-molecule JAK inhibitor being developed for treatment asthma.ObjectiveWe sought to determine whether reduces fractional exhaled nitric oxide (Feno), JAK1-dependent biomarker airway inflammation, in patients with mild asthma.MethodsWe conducted double-blind, randomized, placebo-controlled, phase 1 proof-of-activity study adults asthma...
Human immunodeficiency virus, type 1 (HIV-1) replication requires the interaction of Tat protein with human cyclinT1 (hCyclinT1) subunit positive transcription elongation factor (P-TEFb) complex, which then cooperatively binds to transactivation response element (TAR) RNA transactivate HIV transcription. In this report, a non-immune single-chain antibody (sFv) phage display library was used isolate anti-hCyclinT1 sFvs that could disrupt hCyclinT1-Tat interactions. The N-terminal 272 residues...
The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled a randomized, double-blind, controlled trial for prevention tuberculosis disease latent infection. Plasma concentration-time measurements from 151 (starting at 3-4 months age) receiving 10 to 20 mg/kg/d orally during course 24-month study incorporated population analysis along genotype, body weight, age, sex. results showed...
There are limited data on isoniazid (INH) pharmacokinetics in infants and young children and, therefore, uncertainty appropriate dosing.Pharmacokinetic were obtained from perinatally HIV-exposed South African aged 3-24 months receiving INH 10-20 mg·kg·d orally for Mycobacterium tuberculosis prophylaxis. pharmacokinetic parameters characterized using a population approach. Dosing simulations performed to evaluate weight-based doses based N-acetyltransferase 2 enzyme (NAT2) genotype, age,...
Lipoprotein(a) [Lp(a)] is a risk factor of coronary heart disease, however, its effects on stroke are less well-defined. We performed single-center, retrospective case-control study in 1,953 and 196 ischemic hemorrhagic in-hospital patients, respectively. Controls were healthy individuals that matched for sex age (±5 years) the (1:1 ratio) (1:2 stroke. Lp(a) concentration was measured using latex agglutination turbidimetric method. Logarithmic transformation quartile categorization applied...
4525 Background: GDC-0980 (G) is a potent oral dual pan-PI3K and mTOR (TORC1/2) inhibitor that has been evaluated in multiple solid tumors Phase I II. Everolimus (E) inhibits TORC1 active mRCC post VEGF-TT. This study the first to dirctly test if PI3K/mTOR may improve efficacy over inhibitor. Methods: Clear cell pts who progressed on or after VEGF-TT were randomized (1:1) G (40 mg QD) E (10 QD), stratified by MSKCC score time progression (≤ > 6 months). The primary endpoint was...
Drug-resistant hypertension (RH) is a very high-risk condition involving many hypertensive patients, in whom primary aldosteronism (PA) commonly overlooked. Hence, we aimed at determining if (1) adrenal vein sampling (AVS) can identify PA RH who are challenging because of receiving multiple interfering drugs; (2) AVS-guided adrenalectomy resolve high blood pressure (BP) resistance to treatment these patients. Based on pilot study selected from 1016 consecutive patients referred our Centre...
Abstract GDC‐0810 was under development as an oral anti‐cancer drug for the treatment of estrogen receptor‐positive breast cancer a single agent or in combination. In vitro data indicated that is potent inhibitor OATP1B1/1B3. To assess clinical risk, PBPK model developed to predict transporter drug–drug interaction (tDDI) between and pravastatin human. The constructed Simcyp® by integrating vivo GDC‐0810. prediction human pharmacokinetics (PK) verified using phase I PK data. Simcyp DDI known...